We concluded a prospective study of the value of maintenance therapy in disseminated testicular cancer after chemotherapy-induced complete remission or chemotherapy cytoreduction followed by surgical resection of residual teratoma. A group of 171 patients were randomized to treatment consisting of cisplatin, vinblastine, and bleomycin, or these drugs plus doxorubicin. There was no apparent difference between these two induction regimens. Complete remission was achieved in 113 patients (66 per cent), and 19 (11 per cent) were free of disease by surgical resection of residual tumor. Of the 171 who started, 113 were eligible to receive either maintenance doses of vinblastine (58 patients) or no further therapy (55 patients) after remission-induction therapy. There was a 9 per cent relapse rate during maintenance with vinblastine and a 7 per cent relapse rate with no maintenance therapy; the overall relapse rate was 8 per cent (nine of 113). Our data indicate that maintenance therapy is unnecessary in disseminated testicular cancer.
This article has been cited by other articles:
van den Belt-Dusebout, A. W., de Wit, R., Gietema, J. A., Horenblas, S., Louwman, M. W.J., Ribot, J. G., Hoekstra, H. J., Ouwens, G. M., Aleman, B. M.P., van Leeuwen, F. E.
(2007). Treatment-Specific Risks of Second Malignancies and Cardiovascular Disease in 5-Year Survivors of Testicular Cancer. JCO
25: 4370-4378
[Abstract][Full Text]
Khan, O., Protheroe, A.
(2007). Testis cancer. Postgrad. Med. J.
83: 624-632
[Abstract][Full Text]
Fossa, S. D., Gilbert, E., Dores, G. M., Chen, J., McGlynn, K. A., Schonfeld, S., Storm, H., Hall, P., Holowaty, E., Andersen, A., Joensuu, H., Andersson, M., Kaijser, M., Gospodarowicz, M., Cohen, R., Pukkala, E., Travis, L. B.
(2007). Noncancer Causes of Death in Survivors of Testicular Cancer. JNCI J Natl Cancer Inst
99: 533-544
[Abstract][Full Text]
Bedano, P. M., Brames, M. J., Williams, S. D., Juliar, B. E., Einhorn, L. H.
(2006). Phase II Study of Cisplatin Plus Epirubicin Salvage Chemotherapy in Refractory Germ Cell Tumors. JCO
24: 5403-5407
[Abstract][Full Text]
Kawai, K., Hinotsu, S., Oikawa, T., Sekido, N., Hattori, K., Miyanaga, N., Hasegawa, Y., Kojima, H., Shimazui, T., Akaza, H.
(2006). Treatment Outcome of Metastatic Testicular Cancer at a Single Institution in Japan, a Country with Low Incidence of Germ Cell Tumor. Jpn J Clin Oncol
36: 723-730
[Abstract][Full Text]
Kawai, K., Ando, S., Hinotsu, S., Oikawa, T., Sekido, N., Miyanaga, N., Shimazui, T., Akaza, H.
(2006). Completion and Toxicity of Induction Chemotherapy for Metastatic Testicular Cancer: An Updated Evaluation of Japanese Patients. Jpn J Clin Oncol
36: 425-431
[Abstract][Full Text]
van den Belt-Dusebout, A. W., Nuver, J., de Wit, R., Gietema, J. A., ten Bokkel Huinink, W. W., Rodrigus, P. T.R., Schimmel, E. C., Aleman, B. M.P., van Leeuwen, F. E.
(2006). Long-Term Risk of Cardiovascular Disease in 5-Year Survivors of Testicular Cancer. JCO
24: 467-475
[Abstract][Full Text]
Fizazi, K., Chen, I., Logothetis, C. J.
(2002). Germ-cell tumor survivors: the price for cure. Ann Oncol
13: 187-189
[Full Text]
Fizazi, K., Do, K.-A., Wang, X., Finn, L., Logothetis, C. J., Amato, R. J.
(2002). A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial. Ann Oncol
13: 125-134
[Abstract][Full Text]
Bosl, G. J., Motzer, R. J.
(1997). Testicular Germ-Cell Cancer. NEJM
337: 242-254
[Full Text]
Previous
